In a strategic move to improve healthcare access to diagnostics and reduce dependence on the importation of in-vitro diagnostic kits, Codix Pharma, a Nigerian pharmaceutical company, is set to commission Codix Bio.
Codix Bio is the company’s second in-vitro diagnostics factory in Nigeria, dedicated to the manufacture of rapid diagnostic test kits for Malaria, HIV, HIV/Syphilis Combo, Hepatitis B, Hepatitis C, amongst others.
Nigeria’s Codix Pharma has launched a new initiative to localise rapid diagnostic test kits, a significant breakthrough for the country’s healthcare sector. Previously, nearly 100% of these kits were imported from Europe, North America, and Asia.
This has led to a lack of local manufacturing, causing high costs and limited access to essential services. The launch of Codix Bio is part of a broader continental agenda to build a sustainable health system and contribute to the WHO’s vision. The Federal Government’s support for local pharmaceutical manufacturing is praised. Codix Bio’s kits are subject to stringent quality control measures to meet international standards.
